NanoRepro

NanoRepro EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of NanoRepro (NN6.DE) as of Nov 1, 2026 is 15.45. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -5.29 — a change of -392.23% (higher).

EV/EBIT

15.45

YoY

-392.23%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of NanoRepro is 2025 15.45 . EV/EBIT (Enterprise Value to EBIT) of NanoRepro was 2024 -5.29 . It decreases by -392.23% higher compared to the previous year.

The NanoRepro EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
-16.22 EUR
Jan 1, 2020
6.85 EUR
Jan 1, 2021
0.49 EUR
Jan 1, 2022
-4.23 EUR
Jan 1, 2023
-3.59 EUR
Jan 1, 2024
-5.29 EUR
Jan 1, 2025
15.45 EUR
Jan 1, 2026 (e)
-12.42 EUR
The NanoRepro EV/EBIT history
YEAREV/EBITYoY
est-12.42-180.37%
15.45-392.23%
-5.29+47.37%
-3.59-15.11%
-4.23-955.99%
0.49-92.79%
6.85-142.22%
-16.22-72.62%
-59.24+123.71%
-26.48+52.62%
-17.35+6.44%
-16.30-97.96%
-798.42+2,733.29%
-28.18+216.99%
-8.89+281.55%
-2.33-69.26%
-7.58-48.40%
-14.69—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NanoRepro Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides NanoRepro's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates NanoRepro's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots NanoRepro's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if NanoRepro grows earnings faster than its peers.

NanoRepro Stock analysis

What does NanoRepro do? The Nanorepro AG was founded in 1998 in Marburg an der Lahn and has since developed into a leading company in the development and production of diagnostic rapid tests and self-tests. The company has been listed on the Frankfurt Stock Exchange since 2006 and has its headquarters in the university city of Marburg. Nanorepro's business model focuses on the production and distribution of innovative, reliable, and easy-to-use self-tests for the medical field. The company concentrates on the practical application of the tests - they should be simple, fast, and user-friendly. Nanorepro's core competence lies in the design, production, and distribution of rapid tests and self-tests for the medical field. The company relies on close cooperation with other companies and research institutions to continuously improve the tests and develop new products. Nanorepro focuses on various areas, including the manufacturing of rapid tests and self-tests for the diagnosis of infectious diseases. In addition, the company also offers tests to check pregnancy status or determine ovulation. Nanorepro's range of products also includes self-tests for the early detection of diseases such as diabetes. With its wide range of products, the company is able to address a large customer base and achieve a positive market position. One key product of Nanorepro is the early pregnancy test. This product is easy to handle and allows women to quickly and safely determine if they are pregnant or not. Nanorepro also offers an ovulation test to help women determine the timing of ovulation. Another test offered by the company is the Lyme borreliosis self-test, which allows for the detection of antibodies to Lyme borreliosis. Nanorepro also offers numerous tests for diagnosing infectious diseases. These include tests that can diagnose bacterial or viral infections such as streptococcal infections or hepatitis B and C. The tests are highly accurate and reliable, enabling quick diagnosis and treatment. Another area in which Nanorepro is expanding is the development of self-tests for the early detection of cancer. For this purpose, the company works closely with scientific and research institutions to continuously improve the tests and make them even more precise and reliable. Nanorepro places a strong emphasis on quality control and safety in the production of the tests. The products are CE-certified, ensuring high quality and safety for the user. In addition, the company has been certified according to the standards of the International Quality Management System ISO 13485, guaranteeing a high standard in the production and marketing of medical devices. Overall, Nanorepro AG has established itself as a leading company in the field of rapid tests and self-tests. With its wide range of products and constant willingness to innovate, the company is able to quickly and effectively respond to the requirements of customers and partners. The company's extensive experience in the field of medical diagnostics contributes to Nanorepro being perceived as a reliable partner in medical technology. NanoRepro is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NanoRepro stock

EV/EBIT (Enterprise Value to EBIT) of NanoRepro is 15.45 in 2025.

EV/EBIT (Enterprise Value to EBIT) of NanoRepro changed from -5.29 to 15.45, representing a -392.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) NanoRepro since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s NanoRepro with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — NanoRepro

All Key Metrics — NanoRepro